AR078395A1 - Formas solidas de 3-( 4- amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina-2,6-diona, metodos para hacer las mismas y composiciones farmaceuticas que los contienen - Google Patents

Formas solidas de 3-( 4- amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina-2,6-diona, metodos para hacer las mismas y composiciones farmaceuticas que los contienen

Info

Publication number
AR078395A1
AR078395A1 ARP100103409A ARP100103409A AR078395A1 AR 078395 A1 AR078395 A1 AR 078395A1 AR P100103409 A ARP100103409 A AR P100103409A AR P100103409 A ARP100103409 A AR P100103409A AR 078395 A1 AR078395 A1 AR 078395A1
Authority
AR
Argentina
Prior art keywords
isoindol
oxo
amino
piperidina
dihidro
Prior art date
Application number
ARP100103409A
Other languages
English (en)
Inventor
Inze Lin
Chen-Tung Chen
Original Assignee
Scinopharm Taiwan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scinopharm Taiwan Ltd filed Critical Scinopharm Taiwan Ltd
Publication of AR078395A1 publication Critical patent/AR078395A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicacion 1: Una forma cristalina de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina-2,6-diona que tiene un patron de difraccion de rayos X en polvo a aproximadamente 12,1+- 0,2, 13,4+- 0,2, 18,9+- 0,2, 23,9+- 0,2 y 25,8+- 0,2 grados en dos theta. Reivindicacion 7: Una forma de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina-2,6-diona que amorfa.
ARP100103409A 2009-09-17 2010-09-17 Formas solidas de 3-( 4- amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina-2,6-diona, metodos para hacer las mismas y composiciones farmaceuticas que los contienen AR078395A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24320409P 2009-09-17 2009-09-17

Publications (1)

Publication Number Publication Date
AR078395A1 true AR078395A1 (es) 2011-11-02

Family

ID=43731172

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103409A AR078395A1 (es) 2009-09-17 2010-09-17 Formas solidas de 3-( 4- amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina-2,6-diona, metodos para hacer las mismas y composiciones farmaceuticas que los contienen

Country Status (9)

Country Link
US (1) US8420672B2 (es)
EP (1) EP2477975B1 (es)
JP (1) JP2013505234A (es)
KR (1) KR20120068002A (es)
CN (1) CN102639522A (es)
AR (1) AR078395A1 (es)
AU (1) AU2010296072B2 (es)
TW (1) TWI475014B (es)
WO (1) WO2011034504A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
CN101696205B (zh) * 2009-11-02 2011-10-19 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
MX2013010360A (es) 2011-03-11 2014-04-14 Celgene Corp Formas solidas sde 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-pi peridin-2,6-diona, y sus composiciones farmaceuticas y usos.
US9540341B2 (en) * 2011-07-19 2017-01-10 Amplio Pharma, Llc Crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
CN104016966A (zh) * 2014-01-30 2014-09-03 上海创诺制药有限公司 3-(4-氨基-1,3-二氢-1-氧代-2h-异吲哚-2-基)-2,6-哌啶二酮新晶型及其制备方法
WO2015113314A1 (zh) * 2014-01-30 2015-08-06 上海创诺制药有限公司 3-(4-氨基-1,3-二氢-1-氧代-2h-异吲哚-2-基)-2,6-哌啶二酮新晶型及其制备方法
CN112062751A (zh) * 2017-08-04 2020-12-11 正大天晴药业集团股份有限公司 一种来那度胺的新结晶及其药物组合物
CN108191826A (zh) * 2018-01-08 2018-06-22 浙江省医学科学院 一种来那度胺晶体及其制备方法
RU2723624C1 (ru) * 2019-12-31 2020-06-16 Общество с ограниченной ответственностью «АксельФарм» Наноаморфная форма (rs)-3-(4-амино-1-оксо-1,3-дигидро-2н-изоиндол-2-ил)пиперидин-2,6-дион (варианты), способ её получения и применение для лечения иммунологических или онкологических заболеваний

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
UA83504C2 (en) * 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO2006028964A1 (en) * 2004-09-03 2006-03-16 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
JP2011513497A (ja) * 2008-03-11 2011-04-28 ドクター・レディーズ・ラボラトリーズ・リミテッド レナリドミドの調製
US20110060010A1 (en) * 2008-03-13 2011-03-10 Tianjin Hemay Bio-Tech Co., Ltd Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof
CN102272118A (zh) * 2008-11-03 2011-12-07 基因里克斯(英国)有限公司 来那度胺的晶型及其制备方法
EP2355802A1 (de) 2008-11-14 2011-08-17 Ratiopharm GmbH Intermediate und orale darreichungsformen enthaltend lenalidomid
NZ595492A (en) * 2009-03-02 2013-07-26 Generics Uk Ltd Improved Process for the Preparation of Lenalidomide
DK2403822T3 (en) 2009-03-03 2015-03-02 Chr Hansen As Use of DATEM in the production media for lactic acid bacteria
WO2010129636A2 (en) * 2009-05-08 2010-11-11 Dr. Reddy's Laboratories Ltd. Lenalidomide polymorph
US20120220777A1 (en) * 2009-09-16 2012-08-30 Ranbaxy Laboratories Limited Process for the preparation of a crystalline form of lenalidomide
WO2011061611A1 (en) * 2009-11-19 2011-05-26 Ranbaxy Laboratories Limited Process for the preparation of form b of lenalidomide
CN101817813B (zh) * 2010-01-15 2013-04-10 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮晶体ⅳ及其药用组合物
EP2545043B1 (en) * 2010-03-08 2019-04-24 Natco Pharma Limited Anhydrous lenalidomide form-i

Also Published As

Publication number Publication date
EP2477975A1 (en) 2012-07-25
US8420672B2 (en) 2013-04-16
KR20120068002A (ko) 2012-06-26
TWI475014B (zh) 2015-03-01
AU2010296072B2 (en) 2014-03-27
TW201111357A (en) 2011-04-01
WO2011034504A1 (en) 2011-03-24
AU2010296072A1 (en) 2012-03-22
JP2013505234A (ja) 2013-02-14
EP2477975A4 (en) 2013-03-13
CN102639522A (zh) 2012-08-15
EP2477975B1 (en) 2018-01-10
US20110065750A1 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
AR078395A1 (es) Formas solidas de 3-( 4- amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina-2,6-diona, metodos para hacer las mismas y composiciones farmaceuticas que los contienen
CY1115376T1 (el) Βελτιωμενη μεθοδος
CY1119474T1 (el) Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
EA201391318A1 (ru) Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2,6-диона и их фармацевтические композиции и применение
DK2220076T3 (da) Inhibitorer af replikationen af humant immundefektvirus
WO2013064909A3 (en) Crystalline and non-crystalline forms of sglt2 inhibitors
TR201911140T4 (tr) Btk inhibitörleri olarak heteroaril bileşikleri ve bunların kullanımları.
AR096758A1 (es) Inhibidores cristalinos de bromodominios
BR112016000909A2 (pt) derivados piperidinil indólicos, seus usos, e combinação e composição farmacêuticas
AR078766A1 (es) Formas solidas de n-(4-(7-azabiciclo(2.2.1) heptan-7-il)-2-( trifluorometil) fenil)-4-oxo-5-(trifluorometil)-1,4- dihidroquinolina-3-carboxamida
HN2006014095A (es) Forma cristalina ortorrombica del maleato de asenapina
AR072777A1 (es) Formas solidas de clorhidrato de bendamustina
TR201909743T4 (tr) Amorf CDDO-ME içeren gecikmeli salımlı oral dozaj bileşimleri.
CU20080179A7 (es) Forma galénica divisible que permite una liberación modificada del principio activo
ECSP15004585A (es) Procesos para la preparación de (s)-3-4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona y formas farmacéuticamente aceptables de la misma
CL2012003491A1 (es) Compuesto derivado de dihidropirrol sustituidos; proceso para preparar dichos derivados en forma estereoselectiva.
AR059696A1 (es) Medicamentos que contienen fluoroquinolonas
GT201300084A (es) Conjugado de naloxol-peg cristalino
EA201201109A1 (ru) Прасугрель в тонкоизмельченной кристаллической форме и фармацевтическая композиция, содержащая его
BRPI1014821A2 (pt) "inibidores de replicação de hiv"
ECSP14027739A (es) Métodos para producir clorhidrato de anamorelina que tiene contenido controlado de cloruro
ECSP13012459A (es) Valsartan altamente cristalino
AU2013314244A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A
TR201000689A1 (tr) Sefprozil içeren katı dozaj formlar.
ES2600156T3 (es) Torre modular

Legal Events

Date Code Title Description
FB Suspension of granting procedure